Tag: GlobeNewswire

Global ISO/IEC 42001 certification underscores Altus’ commitment to delivering trusted, transparent and secure AI solutions for the CRE industry

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — Altus Group Limited ( “Altus” or “the Company”) (TSX: AIF), a leading provider of commercial real estate (“CRE”) intelligence, announced today it has achieved ISO/IEC 42001 certification, the world’s first international standard for artificial intelligence (“AI”) management systems.

The certification provides independent validation that Altus’ AI capabilities are governed by a comprehensive framework focused on transparency, accountability, risk management and continuous improvement. It recognizes the Company’s approach to the responsible development, deployment and oversight of AI across its products, services and operations, reinforcing Altus’ leadership in applying trusted, purpose-built AI to CRE analytics.

“In AI, trust is everything,” said Mike Gordon, CEO of Altus. “Our customers rely on Altus to inform some of the most consequential real estate decisions they make. When it comes to AI, they need confidence not only in the data, but also in the technology behind it. Our customers know they can trust the insights we generate because they’re grounded in investment-grade data and deep industry expertise. With ISO/IEC 42001 certification, they can now have the same confidence in the governance, controls, and technology that power those insights. That’s foundational to the commitment we make to our customers – that every decision you make with Altus is one you can stand behind.”

Through the Company’s flagship ARGUS Intelligence Platform and its growing suite of AI agents, Altus helps clients unlock insights from complex real estate data, streamline workflows and improve productivity across the investment lifecycle. As the ARGUS Intelligence Platform becomes more AI-powered, the Company remains focused on ensuring those innovations are developed and deployed responsibly, with appropriate oversight, transparency and safeguards.

Mr. Gordon added: “I’m incredibly proud of the team for achieving this certification on an accelerated timeline, placing Altus among the early adopters of the world’s leading standard for AI management systems. Above all, it reflects our commitment to building AI the right way. As we continue to push the boundaries of what’s possible for the industry, we’re doing it responsibly, with strong governance, transparency and accountability at every step.”

ISO/IEC 42001 establishes internationally recognized requirements for organizations that develop, deploy or use AI systems. The standard provides a framework for managing AI-related risks and opportunities while promoting responsible innovation and effective governance. It complements Altus’ ISO/IEC 27001 certification, the global gold standard for managing and protecting information security through a structured Information Security Management System.

Both the ISO/IEC 42001 and ISO/IEC 27001 certifications further strengthen Altus’ position as a trusted technology partner to the world’s leading real estate investors, developers, lenders and advisors, and reflect the Company’s continued investment in building the next generation of intelligence solutions for the CRE industry – safely and responsibly.

About Altus Group

Altus Group is a leading provider of commercial real estate (“CRE”) intelligence, anchored by ARGUS – the industry’s go-to software for valuation and performance analytics. For more than two decades, Altus has played a vital role in empowering CRE professionals with the analytics and trusted advice they need to make high-impact decisions with confidence. The world’s CRE leaders rely on our market-leading solutions and expertise to drive performance and manage risk. Our people around the world are driving meaningful impact in an industry undergoing unprecedented change – helping shape the cities where we live, work, and build thriving communities.

For more information about Altus (TSX: AIF) please visit www.altusgroup.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Camilla Bartosiewicz 
Chief Communications Officer, Altus Group
(416) 641-9773
camilla.bartosiewicz@altusgroup.com

Lease of the Liberty Magona business unit is now effective, opening a new phase for one of Italy’s historic producers of cold-rolled, galvanized and pre-painted steel

LUGANO, Switzerland and BERTRANGE, Luxembourg, Oct. 05, 2026 (GLOBE NEWSWIRE) — Trasteel Holding S.A. (“Trasteel” or the “Company”), a global steel trading and industrial group (the “Group”) headquartered in Lugano (Switzerland) and Luxembourg, today announced that Trasteel Magona S.r.l. (“Trasteel Magona”), a newly established Group company set up specifically for this transaction, has taken over the operations of the La Magona d’Italia steel plant in Piombino (Tuscany, Italy), following the effectiveness of the lease agreement for the business unit of Liberty Magona S.r.l. (“Liberty Magona”).

The lease agreement, signed on July 29, 2026, became effective on October 1^st, 2026, and will remain in force until December 31, 2027, at the latest. The lease is intended as a first step towards the integration of the business, which has already been contractually agreed and will be completed upon conclusion of the restructuring process initiated by Liberty Magona through the filing with the Court of Florence of a restructuring plan subject to court approval.

The transaction received clearance under Italy’s Golden Power regulations on September 14, 2026, and antitrust clearance from the European Commission on September 29, 2026 (press release).

Founded more than 150 years ago, La Magona d’Italia is one of the historic names of the Italian steel industry and a reference producer of cold-rolled, galvanized and pre-painted flat steel products for customers in Italy and Europe. With the start of the lease, Trasteel Magona will ensure the continuity of the plant’s operations, safeguarding approximately 500 jobs.

Production will restart gradually, in line with a phased plan, with the objective of bringing the plant back to full operation and reaching a production capacity of over 500,000 tonnes per year by the end of 2027.

Trasteel Magona will leverage the Group’s global sourcing, logistics and commercial platform to support continuity, reliability and quality of supply to the plant’s customers.

The Piombino plant complements Trasteel’s Industrial Division, which comprises 13 companies in 6 countries and processes over 800,000 tonnes¹ of steel products per year, including pipes, plates, coils and rebar.

Management Commentary

“Today marks the beginning of a new chapter for La Magona”, said Gianfranco Imperato, CEO of Trasteel. “After several difficult years for the plant, our goal is to bring value back to Piombino’s steel industry and restore Magona to the role it has held for more than a century and a half in the Italian and European steel industry. We strongly believe in the relaunch of the plant and, above all, in the people who work there. Production will restart step by step, supported by the strength of Trasteel’s global sourcing, logistics and commercial platform.”

“This transaction evidences Trasteel’s ability to source and consummate transactions in a competitive environment,” said Steve Salis, Chairman and CEO of Sizzle II. “We are confident in their ability to execute on their business plan to increase shareholder value for the long term.”

Business Combination Agreement

As previously announced on April 13, 2026 (press release), Trasteel has entered into a Business Combination Agreement with Sizzle Acquisition Corp. II (Nasdaq: SZZL) (“Sizzle II”). The business combination is expected to close by the end of 2026, subject to the approval of Sizzle II’s shareholders and other customary closing conditions. Upon closing, the combined company is expected to be listed on the Nasdaq Stock Market under the ticker symbol “TSTL”.

About Trasteel

Trasteel is a global steel trading and industrial group founded in 2009, operating across more than 60 countries with over 1,400 employees. The Company combines trading operations with industrial transformation activities and serves over 4,000 customers worldwide.

For more information, please visit www.trasteel.com

About Sizzle Acquisition Corp. II

Sizzle II is a blank check company, incorporated as a Cayman Islands exempted company, formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. Sizzle II is led by Chairman and CEO Steve Salis and Vice Chairman Jamie Karson. In addition, Sizzle II’s management team includes Daniel Lee, its CFO. Its board of directors is comprised of: Steve Salis, Jamie Karson, Neil Leibman, David Perlin and Warren Thompson. Its board of advisors is comprised of: Rick Camac, Michael Kuchta, Ryan Croft, Craig Curley and Tony Sage.

For more information, please visit https://sizzlespac.com

Additional Information and Where to Find It

This press release is provided for informational purposes only and contains information with respect to the proposed business combination (the “Proposed Business Combination”) pursuant to the business combination agreement, dated April 13, 2026, as amended on September 29, 2026, by and among Sizzle II, Trasteel, a holding company formed by the Trasteel group (“Pubco”), and the other parties thereto (the “Business Combination Agreement”). Subject to its terms and conditions, the Business Combination Agreement provides that at its closing each of Sizzle II and Trasteel will become wholly owned subsidiaries of Pubco.

In connection with the Proposed Business Combination, Pubco intends to file a registration statement on Form F-4 with the Securities and Exchange Commission (“SEC”), which will include a proxy statement to be sent to Sizzle II shareholders and a prospectus for the registration of Pubco securities in connection with the Proposed Business Combination (as amended from time to time, the “Registration Statement”). If and when the Registration Statement is declared effective by the SEC, its definitive proxy statement/prospectus and other relevant documents will be mailed to the shareholders of Sizzle II as of the record date to be established for voting on the Proposed Business Combination and will contain important information about the Proposed Business Combination and related matters. Shareholders of Sizzle II and other interested persons are advised to read, when available, these materials (including any amendments or supplements thereto) and any other relevant documents, because they will contain important information about Sizzle II, Trasteel, Pubco and the Proposed Business Combination. Shareholders and other interested persons will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, and other relevant materials in connection with the Proposed Business Combination, without charge, once available, at the SEC’s website at www.sec.gov or by directing a request to: Sizzle Acquisition Corp. II, 4201 Georgia Avenue, NW, Washington, D.C. 20011, Attn: Steve Salis, Chief Executive Officer. The information contained on, or that may be accessed through, the websites referenced in this press release in each case is not incorporated by reference into, and is not a part of, this press release.

Participants in the Solicitation

This press release is not a solicitation of a proxy from any investor or securityholder. Sizzle II, Trasteel, Pubco and their respective directors and executive officers may be deemed under SEC rules to be participants in the solicitation of proxies from Sizzle II’s shareholders in connection with the Proposed Business Combination. Sizzle II’s shareholders and other interested persons may obtain, without charge, more detailed information regarding the directors and officers of Sizzle II in Sizzle II’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 12, 2026 (the “Sizzle II Form 10-K”). Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Sizzle II’s shareholders in connection with the Proposed Business Combination will be set forth in the proxy statement/prospectus for the Proposed Business Combination, accompanying the Registration Statement that Pubco intends to file with the SEC. Additional information regarding the interests of participants in the solicitation of proxies in connection with the Proposed Business Combination will likewise be included in that Registration Statement. You may obtain copies of these documents, once available, at the SEC’s website at www.sec.gov or by directing a request to the address provided above.

No Offer or Solicitation

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Proposed Business Combination and shall not constitute an offer to sell or a solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ from Trasteel’s expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements include expectations related to the ultimate acquisition of Trasteel Magona, the ability to increase production and maintain a certain employment levels at the plant, the completion of the proposed business combination, Trasteel’s plans, objectives, goals, strategies, future events and performance, and any other statements that are not statements of historical fact. No representations or warranties, express or implied, are given in, or in respect of, this press release. When words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters are used, such terms are, among others, used in the context of making forward-looking statements. Forward-looking statements speak only as of the date they are made. There may be additional risks that are presently unknown, or that Trasteel currently believes are immaterial, which could cause actual results to differ from those contained in the forward-looking statements. For these reasons, among others, you are cautioned not to place undue reliance upon any forward-looking statements in this press release, and Trasteel undertakes no obligation to publicly revise any forward-looking statements to reflect events or circumstances that arise after the date of this press release, except as required by applicable law.

Media Contacts

Trasteel Holding S.A.

Investor Relations
Alessandro Colombi – Head of IR
e-mail: ir@trasteel.com

Media Relations
Alessandro Colombi – Head of IR
e-mail: press@trasteel.com

Investor Relations Advisor

Alpha IR Group
Michael Cummings – President
e-mail: tstl@alpha-ir.com

Media Relations Advisor

Alpha IR Group
James McCusker – Senior Managing Director
e-mail: tstl@alpha-ir.com

---

1 Based on internal management data at FY25, which has not been audited or reviewed by the Company’s independent auditors.

• Company to share insights on the advancing clinical profile and commercial vision for 4D-150
• Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C. Awh, MD, FASRS; Dr. David Eichenbaum, MD, FASRS; and Dr. Sara J. Haug, MD, PhD, will join 4DMT leadership to offer perspective on transforming the treatment paradigm in VEGF-driven retinal diseases
• Live event will take place in New York City on October 21, 2026 at 10:30am ET

EMERYVILLE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the Company will host an Investor Day on Wednesday, October 21, 2026, in New York City. The live event will begin at 10:30am ET and include a Company presentation, KOL panel discussions and a live Q&A session.

Registration for the webcast is available at https://4dmt-investor-day-2026-virtual.open-exchange.net/registration.

An archived copy of the webcast will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate, 4D-150, is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration and the second indication is diabetic macular edema, which are both in Phase 3 development. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™ and the 4DMT logo are trademarks of 4DMT.  

All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Contacts:

Media:
Jenn Gordon
dna Communications
Media@4DMT.com

Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com

Quarter included presentation at H.C. Wainwright Global Investment Conference, strategic partnership with Alpmed, new regulatory registrations, and continued physician training

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — Baird Medical Investment Holdings Ltd. (“Baird Medical” or the “Company”) (NASDAQ: BDMD), a medical device company focused on the development and commercialization of minimally invasive treatment technologies, today highlighted key business and operational developments from the third quarter of 2026, including expansion into new international markets, continued physician training initiatives and the addition of irreversible electroporation (IRE) technology to its broader technology portfolio through a strategic partnership.

“During the third quarter, we continued to execute on the priorities that we believe will drive Baird Medical’s long-term growth, including extension of our geographic reach, strengthening physician adoption and broadening our technology portfolio, while continuing to share our exciting story with the investment community,” said Haimei Wu, Chairwoman and CEO of Baird Medical. “These milestones reflect the progress we are making to build a more diversified global business and create additional opportunities for growth.”

Presenting Baird Medical’s Growth Strategy at H.C. Wainwright

In September, Baird Medical participated in the H.C. Wainwright Global Investment Conference in New York, where U.S. CEO Mark Saxton and Chief Strategy Officer Daphne Huang shared details on the Company’s progress and plans for continued growth.

The presentation highlighted Baird Medical’s expanding U.S. presence, growing adoption of its microwave ablation (MWA) technology and plans to build on its established international business. Management also discussed the Company’s efforts to expand its technology portfolio and reach more physicians and patients across a broader range of markets.

“Our focus this quarter was on execution, including bringing our technology into new markets, working directly with physicians, and adding new capabilities to our portfolio,” said Mark Saxton, U.S. Chief Executive Officer of Baird Medical. “At H.C. Wainwright, we had the opportunity to share that progress with investors and discuss where we see the business going from here. The work underway across our U.S. and international operations gives us a strong foundation as we head into the final months of the year.”

Expanding the Technology Portfolio Through Alpmed Partnership

In August, Baird Medical entered into a strategic partnership with Alpmed focused on the global development and commercialization of next-generation irreversible electroporation (IRE) technology.

The partnership adds another minimally invasive treatment modality alongside Baird Medical’s existing MWA business and provides a path to introduce IRE technology across international markets. The collaboration is part of the Company’s effort to build a broader portfolio of technologies for physicians performing minimally invasive procedures.

Advancing Regulatory and Commercial Expansion in International Markets

Baird Medical also made progress expanding the availability of its MWA technology in new markets during the quarter.

In August, the Company received registrations from the Drug Regulatory Authority of Pakistan (DRAP) for its BD-GT microwave ablation system and T-1610 microwave ablation needle. The registrations allow Baird Medical to bring these products to the Pakistani market and represent another step in the Company’s international expansion.

The Company also marked the completion of first procedures using its MWA technology in Vietnam and Argentina during the quarter, extending the use of its technology into two additional markets.

Connecting with Physicians at Global Medical Conferences

Baird Medical continued its engagement with the international medical community during Q3 through participation in major industry meetings, including the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress and the Asia Pacific Society of Cardiovascular and Interventional Radiology (APSCVIR) Annual Scientific Meeting.

These meetings provided opportunities for the Baird Medical team to connect directly with interventional radiologists and other specialists from around the world, exchange clinical experience, present the Company’s technology in live settings, and discuss developments in minimally invasive treatment.

Expanding Hands-On Physician Training

Physician education remained an important area of focus during the quarter, with Baird Medical supporting training programs in both the U.S. and China.

In the U.S., the Company supported hands-on MWA training in New Orleans, where participating physicians observed procedures and gained practical experience with MWA techniques and applications.

In China, Baird Medical hosted a four-day MWA Master Class for Vietnamese physicians at The Eighth Affiliated Hospital of Sun Yat-sen University, combining clinical observation and hands-on training across multiple MWA applications.

Looking Ahead

As Baird Medical enters the fourth quarter of 2026, the Company remains focused on expanding its presence in key markets, supporting physician education and training, and advancing a broader portfolio of minimally invasive treatment technologies.

The Company expects to continue building on the clinical, commercial, and strategic progress achieved during the third quarter as it works to bring its technologies to more physicians and patients worldwide.

About Baird Medical

Baird Medical is a global, pioneering medical device company specializing in minimally invasive ablation technologies for a range of solid tumors. The Company’s lead product, a microwave ablation (MWA) system, is FDA-cleared for soft tissue ablation and is being launched in the U.S. primarily for the treatment of benign thyroid nodules. In addition, the Company is expanding its minimally invasive technology portfolio, including IRE-based products and an AI-powered robotic ablation system.

Baird Medical’s MWA solutions have been adopted by a growing number of leading U.S. institutions and private practice groups, including the Mayo Clinic, Columbia University Medical Center, and The George Washington University Hospital. The company is rapidly expanding its global commercial footprint, with sales now reaching markets across multiple continents.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical’s future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “could”, “should”, “expect”, “intend”, “might”, “will”, “estimate”, “anticipate”, “believe”, “budget”, “forecast”, “intend”, “plan”, “potential”, “predict”, or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled “Risk Factors” therein, and in ExcelFin’s other filings with the SEC.

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin’s most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein, or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:

Lee Roth
Burns McClellan for Baird Medical
Lroth@burnsmc.com

REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 309, a global, randomized Phase 3 clinical trial evaluating the combination of RASONQUE (daraxonrasib), a RAS(ON) multi-selective inhibitor, and zoldonrasib, an investigational RAS(ON) G12D-selective inhibitor, as a first-line treatment in adult patients with metastatic RAS G12D pancreatic adenocarcinoma (PDAC).

“RAS G12D is the most common RAS variant in PDAC,” said Alan Sandler, M.D., chief development officer of Revolution Medicines. “In preclinical studies, the combination of RAS(ON) multi-selective and G12D-selective inhibitors achieved deeper and more sustained suppression of RAS signaling than either agent alone, accompanied by greater tumor control. Likewise, initial clinical data showed that RASONQUE plus zoldonrasib delivered compelling antitumor activity in patients with previously treated metastatic PDAC, with a manageable safety and tolerability profile. In the context of the unmet need in this patient population, these findings informed the design of the first-line RASolute 309 trial in patients with PDAC. RASolute 309 is the first Phase 3 study evaluating a RAS(ON) inhibitor doublet approach and it marks an important milestone in our efforts to advance a range of potential treatment options for patients with RAS-driven cancers across tumor types and treatment settings.”

RASolute 309 (NCT07805954) is a global, randomized, open-label Phase 3 trial evaluating RASONQUE plus zoldonrasib compared with gemcitabine and nab-paclitaxel (GnP) as a first-line treatment in adult patients with metastatic RAS G12D PDAC. The dual primary endpoints are progression-free survival (PFS) and overall survival. Key secondary endpoints include PFS, objective response rate, duration of response, safety and tolerability, pharmacokinetics, and patient-reported outcomes.

About Pancreatic Adenocarcinoma 

Pancreatic adenocarcinoma, or PDAC, is the most common form of pancreatic cancer and among the most challenging malignancies. Approximately 55,000 people are diagnosed with PDAC in the U.S. each year, and more than 50,000 die from the disease.^1,2 Because early-stage pancreatic cancer often causes few or no symptoms, approximately 80% of patients are diagnosed after the disease has spread, when treatment options are more limited. For patients with metastatic PDAC, the five-year relative survival rate is approximately 3% in the U.S.^3,4 RAS G12D is the most prevalent RAS mutation subtype in PDAC, occurring in 40% of patients.⁵

About Zoldonrasib

Zoldonrasib is an investigational, oral, RAS(ON) G12D-selective, covalent tri-complex inhibitor that binds to cyclophilin A, creating a binary complex that binds to and inhibits the active, oncogenic RAS(ON) G12D mutation. RAS G12D is the most prevalent RAS mutation, accounting for 29% of all RAS-driven cancers.⁵ Across tumor types, approximately 61,000 new patients with RAS G12D cancers are estimated each year in the U.S., and no targeted therapy is currently approved for these patients.⁶ Zoldonrasib is currently being evaluated as a monotherapy and in combination with other therapies, including with RASONQUE, Revolution Medicines’ RAS(ON) multi-selective inhibitor, as well as standard of care regimens in lung and gastrointestinal cancers.

About RASONQUE™ (daraxonrasib)

RASONQUE (daraxonrasib) is an oral, RAS(ON) multi-selective, noncovalent, tri-complex inhibitor, approved by the U.S. FDA for the treatment of adult patients with metastatic pancreatic adenocarcinoma (PDAC) who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.⁷ RASONQUE is being investigated through a global Phase 3 registrational program in patients with PDAC and metastatic RAS mutant non-small cell lung cancer. Outside the U.S., RASONQUE is an investigational agent that has not been approved by any regulatory authority.

U.S. FDA APPROVED INDICATION

RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

IMPORTANT SAFETY INFORMATION FOR U.S. APPROVED INDICATION

RASONQUE is associated with the following Warnings and Precautions: Dermatologic and Soft Tissue Toxicity, Stomatitis and Oral Disorders, Diarrhea, Gastrointestinal Perforation, Interstitial Lung Disease (ILD)/Pneumonitis, and Embryo-Fetal Toxicity.

Serious adverse reactions occurred in 30% of patients treated with RASONQUE. Serious adverse reactions occurring in ≥ 2% of patients treated with RASONQUE were diarrhea (3.7%), pyrexia (3.3%), sepsis (2.9%), fatigue (2.1%), and hemorrhage (2.1%).

The most common (≥ 20%) adverse reactions in patients treated with RASONQUE were rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage.

Please see U.S. Full Prescribing Information for RASONQUE

About Revolution Medicines, Inc.
Revolution Medicines is a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide. For more information, visit www.revmed.com and follow Revolution Medicines on LinkedIn, X (Twitter) and Instagram.

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding the broad potential of RAS(ON) inhibition; prevalence of certain cancer types and mutations; treatment practices; the company’s development strategy; possible adverse reactions; and progression of clinical studies and findings from these studies, including the tolerability, safety, and potential efficacy of the company’s candidates being studied.

Forward-looking statements are typically, but not always, identified by the use of words such as “aims,” “anticipate,” “believe,” “estimate,” “expect,” “plan,” “potential,” “project,” “up to,” “will” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company’s programs’ development stages, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company’s business of global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 5, 2026, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events.

Revolution Medicines Media & Investor Contacts 

Media
media@revmed.com

Investors
investors@revmed.com 

References

¹ Oracle CancerMPact Patient Metrics, Stage IV newly incident + recurrent from earlier stages. Accessed July 2026.
² Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. doi:10.3322/caac.21820
³ Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: Advances and challenges. Cell. 2023;186(8):1729-1754. doi:10.1016/j.cell.2023.02.014
⁴ American Cancer Society. Survival Rates for Pancreatic Cancer. Available at: https://www.cancer.org/cancer/types/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html. Accessed September 2026.
⁵ Lee JK, Sivakumar S, Schrock AB, et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ Precis Oncol. 2022;6(1);91. doi:10.1038/s41698-022-00334-z
⁶ Estimated using tumor mutation frequencies from Foundation Medicine Insights March 2022 and scaled to estimated patient numbers using cancer incidence from ACS Cancer Facts and Figures 2023.
⁷ RASONQUE (daraxonrasib) Prescribing Information. Redwood City, CA: Revolution Medicines, Inc.; August 2026.

• Eligible Aeroplan point donations to the Air Canada Foundation Hospital Transportation Program from October 5–11, 2026, will be multiplied through matching contributions from Aeroplan and its partners
• The Hospital Transportation Program provides transportation for children who require air travel for medical care and treatment not available within their community

MONTRÉAL, Oct. 05, 2026 (GLOBE NEWSWIRE) — Today marks the start of the Aeroplan Points Matching Week in support of the Air Canada Foundation’s Hospital Transportation Program. Members can make donations that will be matched through the support of Aeroplan’s partners until Sunday, Oct. 11, 2026. The program relies on the generous donations from Aeroplan Members to provide relief for families across Canada whose children need to travel for medical care and treatment.

“Each year, Aeroplan Points Matching Week shows the remarkable difference we can make when our members and partners come together in support of children and families who need to travel for essential medical care,” said Éric Lauzon, Director, Community Relations & Partnerships at Air Canada. “We are deeply grateful for the continued generosity of Aeroplan Members and our participating partners, whose support helps ease the journey for families during some of life’s most challenging moments.”

Aeroplan has expanded the group of partners that will participate in this year’s Points Matching Week. Returning partners include TD, CIBC and American Express, while new partners include Hertz, Dollar and Thrifty. Thanks to their generosity, each point donated can have up to eight times the impact, supporting even more children who need to travel for essential medical care. For full details of how points will be matched, please see here.

In 2025, more than 35 million points were donated to the Air Canada Foundation Hospital Transportation Program’s partners, supporting nearly 500 families through 605 trips.

From Patient to National Program Ambassador: Sylas’s Story

At age 13, what first appeared to be a biking accident became a life-threatening medical emergency. The impact forced part of Sylas’s jaw into his skull and caused internal bleeding. He was urgently transferred to BC Children’s Hospital, where a specialized team provided the critical care he needed.

Thanks to the Air Canada Foundation’s Hospital Transportation Program, Sylas and his family travelled between Cranbrook and Vancouver for surgeries, scans and ongoing treatment. By covering the cost of travel, the program removed a significant financial and logistical burden, allowing his family to focus on his recovery. 

“These flights were such a godsend for us. Everything was covered, and it was all done with so much softness and care. It not only eased the financial burden, but it also eased my heart. It meant I could show up for Sylas in every way he needed, without wondering how we were going to manage each trip,” said Jen, Sylas’s mom.

Today, Sylas is 15 and thriving. He is starting Grade 11, works at a local golf course in Kimberley, B.C., and enjoys golfing, mountain biking, camping and spending time on the water. As the 2026 Air Canada Foundation National Hospital Transportation Program Ambassador, Sylas represents the hundreds of children and families who rely on the program to access essential medical treatment far from home.

About the Hospital Transportation Program

For more than 20 years, the Air Canada Foundation’s Hospital Transportation Program has helped children and youth access essential medical care away from home. Powered by Aeroplan point donations and delivered in partnership with 17 partners, including all pediatric hospitals across Canada, the program helps families reach specialized treatment that isn’t available in their community.  

When a child needs medical care far from home, travel can add significant financial, emotional and logistical challenges to an already-difficult time. By reducing these barriers, the program helps families focus on what matters most: their child’s health and well-being. Each year, millions of donated Aeroplan points help connect families to life-changing and, in many cases, life-saving care, while providing peace of mind when it matters most. 

Together with our partners and the generosity of Aeroplan Members, we’re helping ensure that distance is never a barrier to the care that children need. 

About the Air Canada Foundation

The Air Canada Foundation, a not-for-profit organization focused on the health and well-being of children and youth, was launched in 2012. It offers both financial and in-kind support to Canadian-registered charities. Core programs include the Hospital Transportation Program (HTP), which redistributes Aeroplan points to partners of the Air Canada Foundation HTP, including 15 pediatric hospitals across the country, Hope Air and the David Foster Foundation. All donated points enable sick children to access the medical care they need away from home. The Air Canada Foundation, in collaboration with the airline, also engages directly in fundraising activities, such as the Every Bit Counts program that encourages customers to donate loose change of all denominations on board flights or through collection containers available in Air Canada Maple Leaf Lounges. The Foundation also offers continued support to major health-related causes that benefit Canadians and is an active participant in international humanitarian relief activity as the need arises. For more information about the Air Canada Foundation, please read the 2025 Impact Report.

About Air Canada

Air Canada is Canada’s largest airline, the country’s flag carrier and a founding member of Star Alliance, the world’s most comprehensive air transportation network. Headquartered in Montréal, Air Canada provides scheduled service directly to more than 180 airports in Canada, the United States and internationally on six continents. It holds a Four-Star ranking from Skytrax. Air Canada’s Aeroplan program is Canada’s premier travel loyalty program, with more than 10 million members worldwide. Members can earn or redeem points on the world’s largest airline partner network of more than 50 airlines, plus through an extensive range of merchandise, hotel and car rental partners. Through Air Canada Vacations, it offers a selection of vacation and Flight & Hotel packages, tours, cruises, car rentals and experiences. Its freight division, Air Canada Cargo, provides air freight lift and connectivity to hundreds of destinations across six continents using Air Canada’s passenger and freighter aircraft. Air Canada’s climate-related ambition includes a long-term aspirational goal of net-zero greenhouse gas emissions by 2050. For additional information, please see Air Canada’s TCFD disclosure. Air Canada shares are publicly traded on the TSX (AC).

Contacts:        media@aircanada.ca

Internet:          aircanada.com/media

Read our annual report Here

Sign up for Air Canada news: aircanada.com

Media Resources:
Photos
Videos
B-Roll
Articles

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/08fd7adb-657b-4e3b-9925-a2330674f57c

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — Magnite (Nasdaq: MGNI), the largest independent sell-side advertising company, will announce its financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, November 4, 2026. The Company will host a conference call at 1:30 PM (PT) / 4:30 PM (ET) the same day to discuss its financial results and outlook.

Live conference call
Toll free number:	(844) 875-6911 (for domestic callers)
Direct dial number:	(412) 902-6511 (for international callers)
Passcode:	Ask to join the Magnite conference call
Simultaneous audio webcast:	http://investor.magnite.com, under “Events and Presentations”
Conference call replay
Toll free number:	(855) 669-9658 (for domestic callers)
Direct dial number:	(412) 317-0088 (for international callers)
Passcode:	1468027
Webcast link:	http://investor.magnite.com, under “Events and Presentations”

About Magnite

We’re Magnite (NASDAQ: MGNI), the world’s largest independent sell-side advertising company. Publishers use our technology to monetize their content across all screens and formats including CTV, online video, display, and audio. The world’s leading agencies and brands trust our platform to access brand-safe, high-quality ad inventory and execute billions of advertising transactions each month. Anchored in bustling New York City, sunny Los Angeles, mile high Denver, historic London, colorful Singapore and down under in Sydney, Magnite has offices across North America, EMEA, LATAM, and APAC.

Investor Relations Contact
Nick Kormeluk, 949-500-0003
nkormeluk@magnite.com

LITTLE ROCK, Arkansas, Oct. 05, 2026 (GLOBE NEWSWIRE) — Dillard’s, Inc. (“Dillard’s”) (TXSE: DDS) is pleased to announce the launch of Hadley Greene x Gianni Bini, an exclusive, limited-edition fashion collaboration. The collection is available starting today in all Dillard’s stores nationwide and online at dillards.com beginning at 10:00 a.m. CT.

The Hadley Greene x Gianni Bini Collection is available exclusively at Dillard’s.

Born in Texas and raised in Baton Rouge, Louisiana, Hadley Greene is a Los Angeles–based jewelry designer and tastemaker known for her distinct maximalist aesthetic, thoughtful wardrobe curation, and personal style commentary.

“I have fond memories of shopping Dillard’s growing up,” says Greene. “I designed Hadley Greene x Gianni Bini as an ode to my Louisiana heritage and the ease of Los Angeles – the two places that have shaped my sense of creativity and inspiration. We poured an incredible amount of thought and intentionality into every single piece, and everything in the collection has a special, thoughtful backstory.”

A jewelry designer, tastemaker, and storyteller, Hadley is known for a style that strikes the perfect balance between maximalist and timeless, with a one-of-a-kind eye for pieces that feel collected, personal, and enduring. Hadley Greene treats clothing as armor, the first thing you say before you’ve said a word. This collection is that instinct made wearable: expressive, storied, and unmistakably hers.

“We love Hadley’s Baton Rouge roots and her early connection to Dillard’s,” adds Alexandra Dillard Lucie, Vice President of Merchandising. “She brings it all home for our Gianni Bini customer with gorgeous, unique pieces that are sure to inspire head-turning style for every occasion.”

The Hadley Greene x Gianni Bini capsule collection features statement jackets paired with bold separates, dresses, and footwear.

Official Social Channels:

• Hadley Greene Instagram: @hadleyhgreene
• Hadley Greene Substack @hadleyhgreene
• Gianni Bini Instagram: @giannibiniofficial
• Dillard’s Instagram: @dillards

About Hadley Greene
Born in Texas and raised in Baton Rouge, Louisiana, Hadley Greene is a Los Angeles–based jewelry designer and tastemaker. A USC graduate with a degree in Art and Design, she seamlessly blends her passion for effortless expression with a bold, maximalist aesthetic that celebrates individuality. Drawing inspiration from patterns, textures, and unexpected combinations, Hadley crafts jewelry, fashion, and interior designs that are as ornamental as they are authentic. A trailblazer in the fashion and jewelry world, Hadley believes that great design should spark conversation, challenge norms, and inspire creativity. Her work tells an ongoing story of self-expression, where every piece invites a deeper connection with its wearer.

About Gianni Bini
Gianni Bini, Dillard’s largest ladies’ contemporary brand, was launched in 2001 in footwear and later extended to apparel. The mission of Gianni Bini is to remain at the forefront of fashion, offering designs that exude high quality and satisfy the contemporary customer’s constant craving for innovation and trend-forward style. Each season, Gianni Bini delivers fresh yet timeless pieces that speak to every facet of the modern woman’s life.

CONTACT for Dillard’s:
Julie J. Guymon
501-376-5965
julie.guymon@dillards.com

CONTACT for Hadley Greene:
Federica Parruccini
203-253-4196
federica@federicaparruccini.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/2f168e61-0bdd-4789-a516-40424c7d7ff0
https://www.globenewswire.com/NewsRoom/AttachmentNg/8d58d1c3-6178-401d-8b8b-713353abbf46
https://www.globenewswire.com/NewsRoom/AttachmentNg/6ac45f61-d308-458e-84ff-489f66ccdc19
https://www.globenewswire.com/NewsRoom/AttachmentNg/964922e7-7255-4bc4-805f-0b3f21fd2e32
https://www.globenewswire.com/NewsRoom/AttachmentNg/baf630f3-28ea-4a8c-ade2-39da6cc2fcbe
https://www.globenewswire.com/NewsRoom/AttachmentNg/e1fe57bc-abc9-456f-8d22-27152702e540
https://www.globenewswire.com/NewsRoom/AttachmentNg/5b49c60c-8722-482b-9704-6a1b0e43133a
https://www.globenewswire.com/NewsRoom/AttachmentNg/b9fb349d-9775-4920-94c0-a32eaaff7578
https://www.globenewswire.com/NewsRoom/AttachmentNg/cbc26d93-9155-41c9-90a1-a570e96a6853

• The BB-301 pivotal trial remains on track to begin in mid-2027
• Discussions regarding an open-label, single-arm, pivotal study for BB-301 are ongoing, and based on these discussions, the FDA requested additional available data, including data from the Benitec-sponsored OPMD Natural History Study
• Final pivotal study design expected to be confirmed in 1Q 2027
• Benitec will present interim clinical results from the ongoing BB-301 Phase 1b/2a study as a late-breaking poster presentation, which will encompass 12-month follow-up data for all six Cohort 1 patients and interim follow-up data for all three Cohort 2 patients, at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress in Hamburg, Germany, October 27-30, 2026

HAYWARD, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage biotechnology company developing disease-modifying genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (ddRNAi) platform, today announced the receipt of formal feedback from the U.S. Food and Drug Administration (FDA) following the Type C meeting in 3Q 2026.

Discussions regarding an open-label, single-arm, pivotal study for BB-301 are ongoing, and based on these discussions, the FDA requested additional available data, including data from the Benitec-sponsored OPMD Natural History Study. The FDA has agreed to review the relevant information on a timeline that would allow Benitec to confirm the final pivotal study design in 1Q 2027.

Timelines for the BB-301 pivotal study remain on track. Patient enrollment is planned to begin in mid-2027.

“We greatly appreciate the collaboration from the FDA and are encouraged by the constructive nature of our discussions” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. “The OPMD natural history study was designed from the outset to provide a rigorous foundation for the clinical development of BB-301, and the additional available data requested by the Agency represent an important final component of this ongoing development work. We look forward to providing these data to the FDA in the coming weeks and confirming the pivotal study design for BB-301 in the first quarter of 2027. With the comprehensive body of clinical and natural history data generated to date, we remain on track to initiate the pivotal study in mid-2027 and are focused on advancing BB-301 toward becoming the first approved disease-modifying therapy for patients living with OPMD-related dysphagia.”

Benitec will present interim clinical results from the ongoing BB-301 Phase 1b/2a study as a late-breaking poster presentation, which will encompass 12-month follow-up data for all six Cohort 1 patients and interim follow-up data for all three Cohort 2 patients, at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress in Hamburg, Germany, October 27-30, 2026.

About OPMD

There are currently no approved therapies for OPMD, a rare autosomal-dominant degenerative muscle disorder, that impacts nearly 15,000 patients in North America, Europe and Israel. OPMD is caused by a mutation in the poly(A)-binding protein nuclear 1 (PABPN1) gene; PABPN1 is a ubiquitous protein that controls the length of mRNA poly(A) tails, mRNA export from the nucleus and alternative poly(A) site usage. OPMD is a debilitating progressive disease that weakens the pharyngeal muscles, causing severe swallowing difficulties (dysphagia).¹ Progressive dysphagia impacts 97% of OPMD patients and is a severe, life-threatening complication of OPMD which can lead to chronic choking, malnutrition, aspiration pneumonia and death.

About BB-301

BB-301 is a novel, modified AAV9 capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small inhibitory RNAs (siRNAs) against mutant PABPN1 (the causative gene for OPMD). The two siRNAs are modeled into microRNA backbones to silence expression of faulty mutant PABPN1, while allowing expression of the codon-optimized PABPN1 to replace the mutant with a functional version of the protein. BB-301 is administered locally, in a one-time procedure, to the muscles in the throat that drive the swallowing process, an approach designed to maximize local benefit and minimize systemic exposure. We believe the silence and replace mechanism of BB-301 is uniquely positioned for the treatment of OPMD by halting mutant PABPN1 expression while simultaneously providing a functional replacement protein. BB-301 has received Orphan Drug Designation from the EMA and Orphan Drug and Fast Track Designations from the FDA and is currently being evaluated in a Phase 1b/2a, first-in-human, open-label dose escalation study to evaluate the safety and clinical activity of intramuscular doses of BB-301 administered to subjects with OPMD (NCT06185673).

About Benitec Biopharma Inc.

Benitec Biopharma Inc. (NASDAQ: BNTC) is a clinical-stage biotechnology company developing disease-modifying genetic medicines designed to improve the lives of people with life-threatening, genetically defined diseases. The company’s proprietary “Silence and Replace” DNA-directed RNA interference (ddRNAi) platform combines RNA interference, or RNAi, with gene therapy to create medicines designed to facilitate sustained silencing of disease-causing genes and simultaneous delivery of replacement genes that restore normal cellular function following a single administration. The company’s lead investigational candidate, BB-301, is the first and only disease-modifying genetic medicine in clinical development for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release include forward-looking statements, including statements regarding Benitec’s plans to develop and commercialize its product candidates, the timing of the completion of preclinical and clinical trials, the timing of the availability of data from our clinical trials, the timing and sufficiency of patient enrollment and dosing in clinical trials, the timing of expected regulatory filings and other regulatory steps, and the clinical utility and potential attributes and benefits of ddRNAi and Benitec’s product candidates, and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the success of our plans to develop and potentially commercialize our product candidates; the timing of the completion of preclinical studies and clinical trials; the timing and sufficiency of patient enrollment and dosing in any future clinical trials; the timing of the availability of data from our clinical trials; the timing and outcome of regulatory filings and approvals; the development of novel AAV vectors; our potential future out-licenses and collaborations; the plans of licensees of our technology; the clinical utility and potential attributes and benefits of ddRNAi and our product candidates, including the potential duration of treatment effects and the potential for a “one shot” cure; our intellectual property position and the duration of our patent portfolio; expenses, ongoing losses, future revenue, capital needs and needs for additional financing, and our ability to access additional financing given market conditions and other factors; the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business plan; unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities; regulatory developments in the United States of America; the Company’s ability to protect and enforce its patents and other intellectual property rights; the Company’s dependence on its relationships with its collaboration partners and other third parties; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace and market competition; reliance on third party manufacturers and suppliers, and the risks associated with manufacturing complexity, supply interruptions, and compliance with current good manufacturing practices, sales, marketing and distribution requirements for our product candidates; greater than expected expenses; including expenses relating to litigation or strategic activities; our incurrence of significant losses and the uncertainty of our ability to achieve or sustain profitability or generate any revenue; the Company’s ability to satisfy its capital needs through increasing revenue and obtaining additional financing; the impact of local, regional, national and international economic conditions and events; including geopolitical instability, and risks associated with conducting business and seeking regulatory approvals in international markets; our ability to attract and retain key management, scientific, and technical personnel; cyber-security threats and vulnerabilities in our and our third parties’ information technology systems; the impact of legislative and regulatory reforms affecting drug pricing and reimbursement, including Medicare drug-price negotiation and government pricing frameworks; potential product liability claims arising from the use of our product candidates in clinical trials or following any future marketing approval; physicians, patients, third-party payers, or others in the medical community may not be receptive to our product candidates, and we may not generate any future revenue from the sale or licensing of our product candidates; and disruptions to U.S. government agency operations, including FDA staffing changes; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements.

References:

1. https://www.mayoclinic.org/diseases-conditions/dysphagia/symptoms-causes/syc-20372028

Investor Relations Contact:
Candice Masse
astr partners
candice.masse@astrpartners.com

Media Relations Contact:
Audra Friis
Sam Brown Healthcare Communications
(917) 519-9577
audrafriis@sambrown.com

DENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, today announced the entry into definitive agreements on October 2, 2026, for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 854,002 shares of SeaStar Medical’s common stock, originally issued in June 2025, July 2025 and August 2025 (collectively, the “Prior Warrants”), having exercise prices ranging from $6.38 to $7.62 per share, at a reduced exercise price of $3.866 per share, for aggregate gross proceeds of approximately $3.3 million, before deducting placement agent fees and other offering expenses. The shares of common stock issuable upon the exercise of the Prior Warrants are registered pursuant to effective registration statements on Form S-1 (Nos. 333-288065 and 333-289447).

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

In consideration for the immediate exercise of the Prior Warrants for cash, SeaStar Medical will issue new unregistered warrants to purchase up to 1,708,004 shares of common stock. The new warrants will have an exercise price of $3.616 per share, and will consist of (i) warrants to purchase up to 854,002 shares of common stock, exercisable immediately and expiring five years after the effective date of the Resale Registration Statement (as defined below), and (ii) warrants to purchase up to 854,002 shares of common stock, exercisable immediately and expiring eighteen months after the effective date of the Resale Registration Statement.

The offering is expected to close on or about October 5, 2026, subject to the satisfaction of customary closing conditions. SeaStar Medical intends to use the net proceeds of this offering for general corporate purposes, which may include additions to working capital and capital expenditures.

The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “Act”), and, along with the shares of common stock issuable upon their exercise, have not been registered under the Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. SeaStar Medical has agreed to file a registration statement within 30 days of October 2, 2026 with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants (the “Resale Registration Statement”).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. SeaStar Medical is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements related to the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators; (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to secure additional financing on acceptable terms; (vi) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services; (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property; (ix) market and other conditions; and (x) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:  
IR@SEASTARMED.COM

QUELIMMUNE is a registered trademark of SeaStar Medical Holding Corporation.